Alpha 2.0
Login Register
» Authors » Gary E Pakes

Gary E Pakes

Explore the profile of Gary E Pakes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 152
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Microbiology
Top 10 Co-Authors
Lisa L Ross
Qiming Liao
Edwin DeJesus
Keith A Pappa
C Tracey Lancaster
Mark S Shaefer
Kathleen E Squires
Jerry W Snidow
Michael G Sension
Louis M Sloan
Published In
AIDS Res Hum Retroviruses
HIV AIDS (Auckl)
BMC Infect Dis
HIV Clin Trials
AIDS Res Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure
Stainsby C, Perger T, Vannappagari V, Mounzer K, Hsu R, Henegar C, et al.
Pharmacotherapy . 2018 Nov; 39(1):40-54. PMID: 30414209
Introduction: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and...
2.
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
Squires K, Young B, Santiago L, Dretler R, Walmsley S, Zhao H, et al.
HIV AIDS (Auckl) . 2017 Apr; 9:51-61. PMID: 28424561
Purpose: The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. Methods: A total of 369 HIV-infected, antiretroviral-naïve subjects...
3.
Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy
Cespedes M, Castor D, Ford S, Lee D, Lou Y, Pakes G, et al.
J Acquir Immune Defic Syndr . 2013 Jan; 62(5):550-4. PMID: 23314414
Steady-state pharmacokinetics in pregnant women prescribed ritonavir-boosted fosamprenavir (FPV) to prevent HIV transmission were assessed in the second trimester, third trimester, and postpartum. Compared with postpartum, geometric mean amprenavir (APV,...
4.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
Young B, Squires K, Ross L, Santiago L, Sloan L, Zhao H, et al.
AIDS Res Hum Retroviruses . 2012 Oct; 29(2):350-8. PMID: 23039030
Propensity for developing coronary heart disease (CHD) is linked with Framingham-defined cardiovascular risk factors and elevated inflammatory biomarkers. Cardiovascular risk and inflammatory biomarkers were evaluated in ARIES, a Phase IIIb/IV...
5.
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy
Horizon A, Joseph R, Liao Q, Ross S, Pakes G
HIV AIDS (Auckl) . 2011 Nov; 3:53-9. PMID: 22096407
In a retrospective case series study, medical records were evaluated for all male patients infected with human immunodeficiency virus (HIV) diagnosed over a one-year period with foot fractures (n =...
6.
Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population
Rawlings M, Klein J, Klingler E, Queen E, Rogers L, Yau L, et al.
HIV AIDS (Auckl) . 2011 Nov; 3:1-8. PMID: 22096402
Purpose: Renal impairment in human immunodeficiency virus (HIV)-infected patients could potentially be caused by many factors. HIV-related renal impairment risks have been little studied in African Americans and Hispanics. We...
7.
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients
Ross L, Weinberg W, DeJesus E, Fischl M, Horton J, Pappa K, et al.
AIDS Res Hum Retroviruses . 2010 Apr; 26(4):407-17. PMID: 20380480
Population genotyping (PG) can underestimate resistance if resistance-containing low abundance variants go undetected. PG and clonal analysis (CA) results were compared in virologic failures (VFs) from a 48-week clinical trial...
8.
Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II)
Parks D, Jennings H, Taylor C, Pakes G, Acosta E
HIV Clin Trials . 2009 Jul; 10(3):160-7. PMID: 19632955
Purpose: Evaluate how reducing ritonavir (RTV) boosting from 200 mg to 100 mg once daily (QD) affects steady-state pharmacokinetics of components of a fosamprenavir (FPV)-based regimen. Methods: Prospective, open-label, pharmacokinetic...
9.
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Hicks C, DeJesus E, Sloan L, Sension M, Wohl D, Liao Q, et al.
AIDS Res Hum Retroviruses . 2009 Mar; 25(4):395-403. PMID: 19320570
The long-term efficacy of once-daily (qd) fosamprenavir (FPV) 1400 mg boosted by ritonavir 100 mg (FPV/r100) has not been evaluated previously. A 96-week open-label, randomized, multicenter study compared the efficacy/safety...
10.
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy
Eron Jr J, Park J, Haubrich R, Aweeka F, Bastow B, Pakes G, et al.
Antimicrob Agents Chemother . 2009 Mar; 53(6):2335-41. PMID: 19307363
The activities of protease inhibitors in vivo may depend on plasma concentrations and viral susceptibility. This nonrandomized, open-label study evaluated the relationship of the inhibitory quotient (IQ [the ratio of...